Advarra Launches New Technology to Align Patients, Sites, and Sponsors in Clinical Trials
Advarra has announced new technology functionality to its solution, Longboat, an established platform used in more than 70 countries and by nearly 20,000 sites. It now features an online patient portal with a set of engagement tools including a document exchange that enables transparent collaboration between patients, sites, and sponsors or clinical research organizations (CROs) without adding technology burden.
Because the patient portal module is part of the same platform the site uses for essential document collection, training/learning management, study conduct enablement tools, and safety letter viewing and acknowledgement, sites are able to provide a more connected experience for their patients with this workflow.
"We've been listening to sites who are drowning in administrative tasks, repeatedly entering the same information, having to log into multiple systems or feeling out of the loop with direct communication between the sponsor and patient," said Elisa Cascade, chief product officer at Advarra in a press release. "A connected system with site, sponsor, CRO, and patient access provides visibility to all while preserving the site-patient relationship. This transparent collaboration in real time is a win for everyone involved in the study."
Reference
Advarra Launches Next-Generation Technology to Align Patients, Sites, and Sponsors in Clinical Trials. (2023, October 4). Cision PR Newswire.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
